Acute myeloid leukemia(AML) is a malignant tumor of the blood system that is highly heterogeneous in terms of pathogenesis, genetic background and prognostic outcome, with an extremely high fatality rate and recurrence rate. Therefore, exploring new treatment methods and diagnostic strategies is one of the ways to improve the survival rate of patients with acute myeloid leukemia. Circular RNA (circRNA) is a special kind of noncoding RNA, which plays an important role in gene transcription, translation and epigenetic modification, and participates in the disease progression and prognosis of multiple solid tumors. At present, it has found that the abnormal expression of circRNA is closely related to the occurrence, development, drug resistance and prognosis of acute myeloid leukemia.Clinically, it can be used as a new biomarker and potential therapeutic target for AML. This article briefly reviews the research progress of circRNA in acute myeloid leukemia, aiming to provide new strategies for optimizing the diagnosis, treatment and prognosis of leukemia.
题目: 环状RNA在急性髓系白血病中的研究进展.
摘要: . 急性髓系白血病是一种在发病机制、遗传背景和预后转归等方面具有高度异质性的血液系统恶性肿瘤，具有极高的病死率和复发率。因此，探索新的治疗方法和诊断策略是提高急性髓系白血病患者生存率的途径之一。环状RNA (circRNA)是一类特殊的非编码RNA，在基因转录、翻译及表观遗传学修饰等方面发挥重要作用，并参与多种实体瘤的疾病进展及预后。目前研究发现，circRNA的异常表达与急性髓系白血病的发生、发展、耐药及预后密切相关，临床上可作为AML的新型生物标志物及潜在治疗靶点。本文就circRNA在急性髓系白血病中的研究进展作一简要综述，旨在为优化白血病的诊疗及预后评估提供新的策略。.
Keywords: acute myeloid leukemia; circular RNA; prognosis; drug resistance.